Epidemiology of tuberculosis in the world

Seminars in Respiratory and Critical Care Medicine

Volumn 18, Issue 5, 1997, Pages 419-429

  Drobniewski, Francis ^a   Pablos Mendez A ^b   Raviglione, M C ^c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b Columbia University ^*  (United States)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

AIDS; Multiple drug resistant tuberculosis; Short course chemotherapy; Tuberculosis

Indexed keywords

AMINOSALICYLIC ACID; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; AGED; CHILD; DEVELOPING COUNTRY; ENDEMIC DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RATE; MAJOR CLINICAL STUDY; MORTALITY; MULTIDRUG RESISTANCE; MYCOBACTERIOSIS; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; TUBERCULOSIS; TUBERCULOSIS CONTROL;

EID: 0031454653     PISSN: 10693424     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1009357     Document Type: Review

References (98)

1. Raviglione MR, Snider DE, Kochi A. Global epidemiology of tuberculosis - morbidity and mortality of a world-wide epidemic. JAMA 1995;273:220-226
2. Dolin PJ, Raviglione MC, Kochi A. Global tuberculosis incidence and mortality during 1990-2000. Bull World Health Organ 1994;72:213-220
3. Murray CJL, Styblo K, Rouillon A. Tuberculosis in developing countries: Burden, intervention and cost. Bull Int Union Tuberc Lung Dis 1990;65:6-24
4. Jereb JA, Kelly GD, Doolev SW, Cauthen GM, Snider DE. Tuberculosis morbidity in the United States: Final data, 1990. MMWR 1992;40(SS-3):23-27
5. Raviglione MC, Sudre P, Rieder HL, Spinaci S, Kochi A. Secular trends of tuberculosis in Western Europe. Bull World Health Organ 1993;71:297-306
6. Brudney K, Dobkin J. Resurgent tuberculosis in New York City: Human immunodeficiency virus, homelessness, and the decline of tuberculosis control programs. Am Rev Respir Dis 1991;144:745-749
7. WHO Tuberculosis Program. Framework for Effective Tuberculosis Control. Geneva: World Health Organization; 1994. WHO/TB/94. 179
8. Cantwell MF, Snider DE, Cauthen GM, Onorato I. Epidemiology of tuberculosis in the United States, 1985 through 1992. JAMA 1993;272:535-539
9. Drucker E, Alcabes P, Bosworth W, Sckell B. Childhood tuberculosis in the Bronx, New York. Lancet 1994;343: 482-1485
10. Nolan CE, Elarth AM, Barr H, Saeed AM, Risser DR. An out-break of tuberculosis in a shelter for homeless men. Am Rev Respir Dis 1991;143:257-261
11. Perriens JH, Mukadi Y, Nunn P. Tuberculosis and HIV infection: Implications for Africa. AIDS 1991;5(suppl 1):S127-133
12. Rieder HL, Zellweger JP, Raviglione MC, Keizer ST, Migliori GB. Tuberculosis control in Europe and international migration. Eur Respir J 1994;7:1545-1553
13. Ishikawa N. Tuberculosis among immigrants in Japan - epidemiological, clinical and sociological features, and the future of control. Kekkaku 1995;70:691-703
14. Sudre P, ten Dam G, Kochi A. Tuberculosis: A global overview of the situation today. Bull World Health Organ 1992,70:149-159
15. Porter JDH, McAdam KPWJ. Tuberculosis in Africa in the AIDS era - the role of chemoprophylaxis. Trans R Soc Trop Med Hyg 1992;86:467-469
16. Styblo K. Tuberculosis control and surveillance. In: Fleny DC, Perry TI, eds. Recent Advances in Respiratory Medicine. Edinburgh: Churchill Livingstone; 1986:77-108
17. Elliott AM, Luo N, Tembo G, Halwiindi B, Steenbergen G, Machiels L, Pobee J, Nunn P, Haves R, McAdam KPWJ. Impact of HIV on tuberculosis in Zambia: A cross sectional study. BMJ 1990;301:412-415
18. Kessler C, Connolly M, Chaulet P. Tuberculosis Control in Refugees and Displaced Persons. Geneva: World Health Organization; 1996:WHO/TB/96.209
19. Raviglione MC, Rieder HL, Styblo K, Khomenko AG, Esteves K, Kochi A. Tuberculosis trends in eastern Europe and the former USSR. Tubercle & Lung Disease 1994;75:400-416
20. Drobniewski F, Tayler E, Ognatenko N, Paul J, Connolly M, Nye P, Lyagoshina C, Besse C. Tuberculosis in Siberia: 1. An epidemiological and microbiological assessment. Tubercle and Lung Disease. 1996;77:199-206
21. Frieden TR, Fujiwara PI, Washko RM, Hamburg MA. Tuberculosis in New York City - Turning the tide. N Engl J Med 1995,333:229-233
22. Frieden TR, Sherman LF, Maw KL, Fujiwara PI, Crawford JT, Nivin B, Sharp V, Hewlett, D Jr Brudney K, Alland D, Kreisworth BN. A multi-institutional outbreak of highly drug-resistant tuberculosis: Epidemiology and clinical outcomes. JAMA 1996;276:1229-1235
23. Schatz A, Waksman SA. Effect of streptomycin and other antibiotic substances upon Mycobacterium tuberculosis and related organisms Proc Soc Exp Biol Med 1994;57: 244-248
24. Lehman J. Para-aminosalicylic acid in the treatment of tuberculosis. Lancet 1946;1:15-16
25. Bernstein J, Lott WA, Steinburg BA, Yale HL. Chemotherapy of experimental tuberculosis V. Isonicotinic acid hydrazide (Nydrazid) and related compounds. Am Rev Tuberc 1952;65:357-364
26. Drolet GJ. Present trend of case fatality rates in tuberculosis. Am Rev Tuberc 1938;37:125-151
27. Narain R, Gothi GD, Nair SS et al. National Tuberculosis Institute, Bangalore. Tuberculosis in a rural population of South India: A five year epidemiologic study. Bull World Health Organ 1974;51:473-488
28. Medical Research Council. Streptomycin treatment of pulmonary tuberculosis. BMJ 1945;2 769-782
29. Medical Research Council. Treatment of pulmonary tuberculosis with streptomycin and para-amino salicyclic acid. BMJ 1950;2:1073-1086
30. MRC Tuberculosis Chemotherapy Trials Committee. Long term chemotherapy in the treatment of chronic pulmonary tuberculosis with cavitation. Tubercle 1962;43:201-267
31. Pfuetze KH, Pyle MM, Hinshaw HC, Feldman WH. The first clinical trial of streptomycin in human tuberculosis. AM Rev Tuberc 1955;71.752-754
32. Coombs DL, Geiter LJ, O'Brien RJ. The UHPS tuberculosis short-course chemotherapy trial 21. Ann Intern Med 1990;112:397-406
33. China Tuberculosis Control Collaboration. Results of directly observed short course chemotherapy in 112 842 Chinese patients with smear-positive tuberculosis. Lancet 1996;347:358-362
34. East African/British Medical Research Council. Controlled clinical trial of short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Lancet 1972;I:1079-1085
35. East African/British Medical Research Council. Co-operative Investigation. Controlled clinical trial of four short course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis. Lancet 1974;2 1100-1106
36. East African/British Medical Research Council Study. Results at 5 years of a controlled comparison if 6-month and a standard 18-month regimen of chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis 1977;116: 3-8
37. East African/British Medical Research Council. Controlled clinical trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis. Am Rev Respir Dis 1978,118:39
38. British Thoracic and Tuberculosis Association. Shortcourse chemotherapy in pulmonary tuberculosis. A controlled trial by the British Thoracic and Tuberculosis Association. Lancet 1976;2:1102-1104
39. Frieden TR, Sherman LF, Maw KL, Fujiwara PI, Crawford JT, Nivin B, Sharp V, Hewlett D Jr, Brudney K, Alland D, Kreisworth BN. A multi-institutional outbreak of highly drug-resistant tuberculosis: epidemiology and clinical outcomes. JAMA 1996:1229-1235
40. Pablos-Méndez A, Sterling TR, Frieden TR. The relationship between delayed or incomplete treatment and allcause mortality in patients with tuberculosis. JAMA 1996; 276:1223-1228
41. Israel HL. Chemoprophylaxis for tuberculosis Respir Med 1993;87:81-83
42. WHO Global Tuberculosis Program. Global Tuberculosis Control. WHO Report. Geneva: World Health Organization, 1997:WHO/TB/97.225
43. De Cock KM, Soro B, Coulibaly IM, Lucas S. Tuberculosis and HIV infection in sub-Saharan Africa. JAMA 1992;268: 1581-1587
44. Drobniewski FA, Pozniak A, Uttley AHC. TB and AIDS. J Med Microbiol 1995;43:85-91
45. Ellner JJ, Hinman AR, Dooley SW, Fischl MA, Sepkowitz KA, Goldberger MJ, Shinnick TM, Iseman MD, Jacobs WR. Tuberculosis symposium: Emerging problems and promise. J Infect Dis 1993;168:537-551
46. Chaisson RE, Schecter GF, Theuer CP, Rutherford GW, Echenberg OF, Hopewell PC. Tuberculosis in patients with the acquired immunodeficiency syndrome. Am Rev Resp Dis 1987;136:570-574
47. Nunn P, Brindle R, Carpenter L, Odhiambo J, Wasunna K, Newnham R, Githui W, Gathua S, Omwega M, McAdam K Cohort study of HIV infection in tuberculosis patients. Nairobi, Kenya: Analysis of early (6 months) mortality. Am. Rev Resp Dis 1992;146:849-854
48. Daley CL, Small P, Schector G, Schoolnik G, McAdam R, Jacobs W, Hopewell P. An outbreak of tuberculosis with accelerated progression among persons infected with human immunodeficiency virus. N Engl J Med 1992;326. 231-235
49. McCray E, Onorato IM, Miller BI, Dondero TJ, Bloch AB. Estimating HIV levels and trends among patients of tuberculosis clinics. Public Health Rep 1990;105:135-140
50. Eriki PP, Okwera A, Aisu T, Morrissey AB, Ellner JJ, Daniel TM. The influence of human immunodeficiency virus infection on tuberculosis in Kampala, Uganda. Am Rev Resp Dis 1991;143:185-187
51. Drobniewski FA. Is death inevitable with multiresistant TB plus HIV infection? Lancet 1997;349:71-72
52. Selwyn PA, Hartel D, Lewis VA, Schoenbaum EE, Vermund SH, Klein RS, Walker AT, Friedland GH. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989;320:545-550
53. Antonucci G, Girardi E, Raviglione MC et al. Risk factors for tuberculosis in HIV-infected persons. A prospective cohort study. JAMA 1995;274:143-148
54. Sutherland I. Recent studies in the epidemiology of tuberculosis, based on the risk of being infected with tubercle bacilli. Adv Tuberc Res 1976;19:1-63
55. Chintu C, Bhat G, Luo C, Raviglione M, Diwan V, Dupont HL, Zumla A. Seroprevalence of human immunodeficiency virus type 1 infection in Zambian children with tuberculosis. Pediatr Infect Dis J 1993;12:499-504
56. Alland D, Kalkut GE, Moss AR, McAdam RA, Hahn JA, Bosworth W, Drucker E, Bloom B. Transmission of tuberculosis in New York City - an analysis by DNA fingerprinting and conventional epidemiological methods. N Engl J Med 1994,330:1710-1716
57. Small PM, Hopewell PC, Singh SP, Paz A, Parsonnet J, Ruston DC, Schecter GF, Daley CL, Schoolnik GK. The epidemiology of tuberculosis in San Francisco - a population-based study using conventional and molecular methods. N Engl J Med 1994;330.1703-1709
58. Hubert B, Pelletier A. Les cas déclarés de tuberculose en France en 1990. Bulletin Epidemiologique Hebdomadaire 1991;48/91.207-208
59. Vareldzis BP, Grosset J, de Kantor I, Crofton I, Laszlo A, Felten M, Raviglione MC, Kochi A. Drug-resistant tuberculosis: Laboratory issues. Tubercle 1994;75:1-7
60. Edlin BR, Tokars JL, Grieco MH, Crawford JT, Williams J, Sordillo E, Ong KR, Kilburn JO, Dooley SW, Castro KG, Jarvis WR, Holmberg SD. An outbreak of multi-drug resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. N Engl J Med 1992;26:1514-1521
61. WHO/IUATLD Global Working Group on Drug Resistance Surveillance. Guidelines for surveillance of drug resistance in tuberculosis. Geneva: World Heath Organization; 1997;WHO/TB/96.216
62. Goble M, Iseman MD, Madsen LA, Watte D, Ackerson L, Horsburgh CR. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993;328 527-532
63. Coronado VG, Beck-Sague CM, Hutton MD et al. Transmission of multidrug-resistant Mycobacterium tuberculosis among persons with human immunodeficiency virus infection in an urban hospital: epidemiologic and restriction fragment length polymorphism analysis. J Infect Dis 1993;168:1052-1055
64. Small PM, Shafer RW, Hopewell PC, Singh SP, Murphy MJ, Desmond E, Sierra MF, Schoolnik GK. Exogenous reinfection with multi-drug resistant Mycobacterium tuberculosis in patients with advanced HIV infection. N Engl J Med 1993;328:1137-1144
65. Centers for Disease Control. Nosocomial transmission of multidrug resistant tuberculosis among HIV-infected persons - Florida and New York 1988-91 MMWR 1991;40: 585-591
66. Frieden TR, Sterling T, Pablos-Mendez A, Kilburn JO, Cauthen GM, Dooley SW. The emergence of drug-resistant tuberculosis in New York City. N Engl J Med 1993;328: 521-526
67. Fischl MA, Uttamchandani RB, Daikos GL, Poblete R, Moreno J, Reyes R, Boota AM, Thompson LM, Cleary TJ, Lai S An outbreak of TB caused by multi-drug resistant tubercle bacilli among patients with HIV infection Ann Intern Med 1992;117:177-183
68. Beck-Sague C, Dooley S, Hutton M, Otten J, Breeden A, Crawford JT, Pitchenik AE, Woodley C, Cauthen G, Jarvis WR. Hospital outbreak of multi-drug resistant Mycobacterium tuberculosis infections: Factors in transmission to staff and HIV-infected patients. JAMA 1992;268:1280-1286
69. Pearson ML, Jereb JA, Frieden TR, Crawford JT, Davis BJ, Dooley SW, Jarvis WR. Nosocomial transmission of multidrug resistant Mycobacterium tuberculosis: A risk to patients and health care workers. Ann Intern Med 1992;117: 191-196
70. Monno L, Angarano G, Carbonara S et al. Emergence of drug resistant Mycobacterium tuberculosis in HIV-infected patients. Lancet 1991;337:852
71. Bouvet E. Transmission nosocomiale de tuberculose multi-résistante parmi les patients infectés par le VIH : en France, à Paris. Bulletin Epidémiologique Hebdomadaire 1991;45:196-197
72. Herrera D, Cano R, Godoy P et al. Multidrug-resistant tuberculosis outbreak on an HIV ward - Madrid, Spain, 1991-1995. MMWR 1996,45:330-333
73. Iseman MD. Treatment of multidrug-resistant tuberculosis. N Engl J Med 1993;329:784-791
74. Bloch AB, Cauthern GM, Onorato IM et al. Nation-wide survey of drug-resistant tuberculosis in the United States. JAMA 1994;271:665-671
75. Sepkowitz KA, Telzak EE, Recalde S, Armstrong D, the New York City Area Tuberculosis Working Group. Trends in the susceptibility of tuberculosis in New York City. 1987-1991. N Engl J Med 1993,328:521-526
76. Dawson D, Anargyros P, Blackblock Z et al. Tuberculosis in Australia: An analysis of cases identified in reference laboratories in 1986-88. Pathology 1991;23:130-134
77. Warburton ARE, Jenkins PA, Waight PA, Watson JM. Drug resistance in initial isolates of Mycobacterium tuberculosis in England and Wales, 1982-1991. Commun Dis Rep CDR Rev 1993,3:R175-R179
78. National Institute Microbiology, Buenos Aires. National drug resistance surveillance World Health Organisation. Global Tuberculosis Program Country Reports. Geneva: World Health Organization: 1994.
79. National Institute of Public Health and Environment, RIUM. Drug Resistance in the Netherlands. Bilthoven, the Netherlands; 1994.
80. Valenzuela MT, Garcia P, Ponce J, Lepe R, Velasco M, Piffardi S. Drug resistance of M. tuberculosis in Chile: Rates of initial resistance for 1986 and acquired resistance for 1985. Bull Int Union Tuberc Lung Dis 1989;64:13-14
81. Instituto de Salud Publica de Santiago, Chile. National drug resistance surveillance. World Health Organization. Global Tuberculosis Program Country Reports Geneva: World Heath Organization: 1992
82. Githui WA, Kwamanga D, Chakaya JM, Karimi FG, Waiyaki PG. Antituberculosis initial drug resistance of Mycobacterium tuberculosis in Kenya: A ten-year review. East Afr Med J 1993;70:609-612
83. Glynn JR, Jenkins PA, Fine PEM et al. Patterns of initial and acquired antituberculosis drug resistance in Karonga District, Malawi. Lancet 1995;345:907-910
84. Curran M, Dawson D, Cheah D. Laboratory surveillance of Mycobacterium tuberculosis isolates in Australia, 1992. Communicable Disease Intelligence 1994;18:337-339
85. Bennett DE, Brady AR, Herbert J et al. Drug resistant tuberculosis in England and Wales, 1993-5. Thorax 1996;51 (suppl3):S32
86. National Tuberculosis/Leprosy Programme in Tanzania. Summary reports, 1991-1995. National drug resistance World Health Organization 6106.1. Tuberculosis Programme Country Reports. Geneva: World Health Organization
87. Yates MD, Grange JM. A bacteriological survey of tuberculosis due to the human tubercle bacillus (Mycobarterium tuberculosis) in south-east England: 1984-91. Epidemiol Infect 1993;110 609-619
88. Kim SJ, Hong YP. Drug resistance of Mycobacterum tuberculosis in Korea. Tuberc Lung Dis 1992;73:219-224
89. Zhang LX, Kan GQ, Tu DH, Li JS, Liu XX. Trend of initial drug resistance of tubercle bacilli isolated from new patients with pulmonary tuberculosis and its correlation with the tuberculosis program in Beijing. Tuberc Lung Dis 1995;76:100-103
90. Githui WA, Juma ES, van Gorkom J, Kibuga D, Odhiambo J, Drobniewski FA. Anti-tuberculosis drug resistance surveillance in Kenya, 1995. In press
91. Cohn D, Bustreo F, Raviglione MC. Drug resistant tuberculosis: Review of the worldwide situation and the WHO/ IUATLD Global Surveillance Project. Clin Infect Dis 1997;24(suppl 1):S121-S130
92. Zhang Y, Young D. Molecular genetics of drug resistance in Mycobacterium tuberculosis. J Antimicrob Chemother 1994; 34:313-319
93. Telenti A, Imboden P, Marchesi F et al. Detection of rifampin-resistance mutations in Mycobacterium tuberculosis. Lancet 1993;341:647-650
94. Heym B, Honore N, Truffot-Pernot C, et al. Implications of multidrug resistance for the future of short course chemotherapy of tuberculosis: A molecular study. Lancet 1994;344:293-298
95. Miller LP, Crawford JT, Shinnick TM. The rpo B gene of Mycobacterium tuberculosis. Antimicrob Agents Chemother 1994;38:805-811
96. Bustreo F, Migliori GB, Nardini S, Raviglione MC. Antituberculosis drug resistance: Is it worth measuring? Monaldi Arch Chest Dis 1996;51:299-302
97. Canetti G, Froman S, Grosset J et al. Mycobacteria: Laboratory methods for testing drug sensitivity and resistance. Bull World Health Organ 1963,29:565-578
98. Canetti G, Fox W, Khomenko A et al. Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programs. Bull World Health Organ 1969;41:21-43